We recently published a list of 10 Stocks With At Least $30 Million In Insider Sales Recently. In this article, we are going to take a look at where Cencora, Inc. (NYSE:COR) stands against other stocks with at least $30 million in insider sales recently.
Last week, stocks declined in part due to President Donald Trump’s statements on tariffs. This week, the turbulent ride on the stock market continues as stocks react to the President’s comments on a potential recession.
In an interview on Fox News’ “Sunday Morning Futures with Maria Bartiromo” that aired Sunday, Trump discussed the U.S. economy, stating it is “a period of transition,” and did not rule out a possible recession, according to CNN Business. When directly asked if he was expecting one, the President responded, “I hate to predict things like that. There is a period of transition because what we’re doing is very big.”
The very big U.S. indexes reacted to the news, with blue-chip companies dropping by 1%, and the broader market index losing 2%. The NASDAQ, which already entered correction last week, fell another 3% today. Tech stocks were leading the sell-off.
As the market adapts to new political and economic developments, some analysts remain optimistic, with faith in the future adoption of AI technology. During these market fluctuations, insider trading often attracts attention, as executives have valuable insights into their company’s future. For instance, when a CEO or CFO buys company stock, it can signal confidence in the company’s prospects.
On the other hand, selling shares may indicate a lack of confidence, though it’s not always the case. Insiders may sell for reasons like portfolio rebalancing or personal financial needs, and many follow pre-arranged trading plans (10b5-1 plans).
While insider buying or selling can offer useful clues, it should be considered alongside a company’s financial health, industry trends, and market conditions. Research is key to making informed investment decisions.
Today, we’re focusing on stocks that have seen insider sales of at least $30 million since the start of the year. Using Insider Monkey’s insider trading screener, we identified stocks where at least one insider sale reached $30 million or more. While the total value of insider sales for these stocks could be higher, we specifically selected the stocks with the single largest insider sale above $30 million. From this group, we highlighted the 10 stocks with the highest individual insider sales.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
For each stock, we provide details on the highest individual sale, the number of insider sales exceeding $30 million year-to-date, and the company’s current market capitalization.
A well-stocked pharmacy shelf full of the company’s pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products.
Cencora, Inc. (NYSE:COR)
Highest Individual Sale: $264,531,701.35
Number of Sales Above $30 million: 2
Market Capitalization: $49.32 billion
Cencora, Inc. (NYSE:COR), previously known as AmerisourceBergen Corporation sources and distributes pharmaceutical products both in the U.S. and internationally. The Conshohocken, Pennsylvania-headquartered company operates in two segments – U.S. Healthcare Solutions and The International Health Solutions. Across the U.S. Cencora provides pharmaceuticals, over-the-counter products, home healthcare supplies, and related services to hospitals, pharmacies, clinics, and long-term care providers. It also offers pharmacy management, staffing, packaging, clinical trial support, and data analytics services. Additionally, it distributes animal health products, blood products, vaccines, and specialty drugs to various healthcare providers.
On February 2, one insider sold $264.53 million worth of Cencora shares for $244.51 per share. Year-to-date, the stock is up 16.03%, trading at $260.69 per share. Over the past 12 months, Cencora brought back 9.68% to its investors.
On February 6, the company confirmed it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale of Cencora shares.
Cencora (NYSE:COR) also recently reported that in its fiscal year 2025 first quarter revenue increased 12.8% year-over-year to $81.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.50 for the first quarter of fiscal 2025 compared to $2.98 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 13.7% to $3.73 in the fiscal first quarter from $3.28 in the prior year first quarter.
According to 10 analysts, Cencora stock is a “Buy” with a price target of $274.8, writes StockAnalysis. The average price target presents a 5.25% upside from the previous price.
Cencora (NYSE:COR) is one of the top 10 stocks analysts are watching as AI selloff deepens.
Overall, COR ranks 9th on our list of stocks with at least $30 million in insider sales recently. While we acknowledge the potential of COR, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than COR but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. This article is originally published at Insider Monkey.
